EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

19 June 2026
EMA/CVMP/105182/2026
Committee for Veterinary Medicinal Products

Summary of opinion[1] (initial authorisation)

Nobivac NXT HCPFeLV

Common name: Feline calicivirosis, feline rhinotracheitis, feline panleucopenia (live) and feline leukemia (RNA replicon particle) vaccine

On 18 June 2026, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion[2], recommending the granting of a marketing authorisation for the veterinary medicinal product Nobivac NXT HCPFeLV, lyophilisate and solvent for suspension for injection, intended for use in cats. The applicant for this veterinary medicinal product is Intervet International B.V.

Nobivac NXT HCPFeLV is an immunological veterinary medicinal product (vaccine) containing 'feline herpesvirus 1, strain G2620A (live), feline calicivirus, strain F9 (live), feline panleucopenia virus, strain MW-1 (live) and feline leukemia virus (strain A/Glasgow-1), gp85 gene encoded by Venezuelan equine encephalitis virus (strain TC-83), self-amplifying RNA, viral particle, replication deficient' as the active substances.

The benefits of Nobivac NXT HCPFeLV are its efficacy for the active immunisation of cats:

- to reduce mortality, clinical signs and virus excretion caused by infection with feline herpesvirus (FHV) type 1 (feline rhinotracheitis virus);
- to reduce clinical signs and virus excretion caused by infection with feline calicivirus (FCV);
- to prevent mortality, clinical signs, leucopenia and virus excretion caused by infection with feline panleucopenia virus (FPL);
- to reduce persistent viraemia and clinical signs caused by feline leukemia virus (FeLV).

The onset of immunity is 1 week. The duration of immunity is 1 year after primary vaccination or 3 years after re-vaccination for FHV, FCV and FeLV and 3 years for FPL. A prevention in persistent viraemia and in clinical signs associated with feline leukemia virus has been demonstrated for 1 year after primary vaccination or revaccination.

[1] Summaries of opinion are published without prejudice to the Commission Decision.
[2] Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Nobivac NXT HCPFeLV is generally well tolerated at the recommended dose. The most common side effects are injection site swelling and elevated temperature (common).

Detailed conditions for the use of this product are described in the summary of product characteristics (SPC) which will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

The CVMP, on the basis of quality, safety and efficacy data submitted, considers that there is a favourable benefit-risk balance for Nobivac NXT HCPFeLV and therefore recommends the granting of the marketing authorisation.